首页> 外文期刊>JK Science : Journal of Medical Education & Research >Critical Analysis of Quality Adverse Drug Reaction Related Published Reports in Indian Biomedical Journal
【24h】

Critical Analysis of Quality Adverse Drug Reaction Related Published Reports in Indian Biomedical Journal

机译:印度生物医学杂志中有关药物不良反应的质量报告的批评性分析

获取原文
           

摘要

To critically analyze the quality of medical contents of published ADR reports in Indian biomedical Journals. The current descriptive observational study evaluated case reports of last 2 years published in two standard Indian journals from the field of pharmacology and Pharmacotherapeutics with PV as scope. The international society of epidemiology (ISPE) and the international society of pharmacovigilance (ISoP) joint recommendations for submitting ADR's for publication were used. Out of 96 ADE's 86.45% were ADRs, 10.41% drug interactions & 3.13% medication errors. 22.91% were new drugs and 78.12% were due to old drugs. 66.67% & 25.00% of ADRs were rare and unusual respectively. 14.58% of the cases was seriousness/life threatening and 4.17% of cases were fatal. 14.5% & 19.7% cases were type A & B reactions respectively. 98.95% of the reports provided information about drug dosage, duration, route and formulation. Naranjo and WHO scale were not used in 21.88% and 56.25% of cases respectively. Severity scale and preventability scale were not applied in 90.63% and 94.79% of cases. Temporal relationship was not clear in 4.21% cases while medical contents were inadequate in 42.71% of cases. In 83.33% dose response relationship was not seen. Pictorial evidence was lacking in 48.9% & drug estimation in 92.71% cases. Other offending drug or pathology was present in 53.13% cases. In 19.79% of cases investigations were present but inadequate.The quality & Medical contents of published ADR reports in Indian journals are inadequate in various aspects which need improvisation.
机译:严格分析印度生物医学期刊中已发表的ADR报告的医学内容质量。当前的描述性观察性研究以PV为范围,评估了来自印度药理学和药物治疗学领域的两种标准印度期刊上发表的最近两年的病例报告。使用了国际流行病学学会(ISPE)和国际药物警戒学会(ISoP)提交ADR公开发表的联合建议。在96例ADE的86.45%中,ADR,10.41%的药物相互作用和3.13%的用药错误。新药占22.91%,旧药占78.12%。 66.67%和25.00%的ADR分别为稀有和不寻常。 14.58%的事件是严重/危及生命,而4.17%的事件是致命的。 A型和B型反应分别为14.5%和19.7%。 98.95%的报告提供了有关药物剂量,持续时间,途径和配方的信息。分别没有使用Naranjo和WHO量表的比例为21.88%和56.25%。 90.63%和94.79%的病例未应用严重性量表和可预防性量表。时间关系不明确的占4.21%,而医疗内容不足的占42.71%。在83.33%中未发现剂量反应关系。在48.9%的病例中没有图形证据,在92.71%的病例中没有药物估计。 53.13%的病例中存在其他违规药物或病理。目前有19.79%的案件进行了调查,但调查不充分。印度期刊上已发布的ADR报告的质量和医学内容在各个方面均不足,需要即兴进行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号